According to the agreement, Vicor’s PD2i cardiac analyzer will be used by University of Rochester personnel to identify which of the 651 congestive heart failure patients who participated in the Music trial suffered sudden cardiac death.
During the average 44 months Music trial participants were followed, 52 died from sudden cardiac death. Vicor expects to have the results of its Music trial data analysis during the second quarter of 2009.
David Fater, president and CEO of Vicor, said: “We are extremely excited to be able to have this opportunity to analyze the Music trial patient data with our PD2i cardiac analyzer. An archive of analyzable data such as this – which is unusual to obtain – is a major accomplishment, as it enables us to quickly and cost-effectively produce a statistically significant clinical dataset.”